CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 3
ANALYST CREDENTIALS 4
BCC ONLINE SERVICES 4
DISCLAIMER 5

CHAPTER TWO: EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, 2008-2015 ($ MILLIONS) 7
EXECUTIVE SUMMARY (CONTINUED) 8

CHAPTER THREE: OVERVIEW 9
CURRENT STATE OF CENTRAL NERVOUS SYSTEM DISEASE 9
ESTABLISHED DRUG SEGMENTS 10
PSYCHIATRY 10
DEPRESSION 10
MULTIPLE SCLEROSIS / PARKINSON'S 10
EPILEPSY/CONVULSION 11
ALZHEIMER'S 11
ATTENTION DEFICIT HYPERACTIVITY DISORDER/NARCOLEPSY 11
MIGRAINE 11
OTHER 12
KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM MARKET 12
2009 FDA PEDIATRIC ADVISORY COMMITTEE ON PRESCRIPTION OF ANTIPSYCHOTICS 12
GROWTH SEEN VIA PURSUIT OF ADDITIONAL INDICATIONS VERSUS NCE APPROVALS 13
ALZHEIMER'S DRUGS IN JAPAN OPEN UP LARGE OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS 13
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 13
TABLE 1 RECENTLY APPROVED AND PIPELINE FORECAST, 2009-2015 ($ MILLIONS) 14

CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS 15
INDUSTRY STRUCTURE 15

TABLE 2 CENTRAL NERVOUS SYSTEM MARKET SEGMENTS: SIZE, GROWTH, SHARE ($ MILLIONS) *16*
MARKET CONCENTRATION AND PRICE SENSITIVITY 17
TABLE 3 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS) *18*
TABLE 3 (CONTINUED) *19*
MARKET TRENDS 19
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume 19
Significant Impact of Patient Advocacy Groups in CNS Disease 20
Growth Seen via Pursuit of Additional Indications versus NCE Approvals 20
Improving Performance in Depression Treatments 20
Alzheimer's Therapy Continues to Receive Large and Important Investment 20
TABLE 4 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM DRUGS, 2010 AND 2015 ($ MILLIONS) *21*
TABLE 5 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS) *22*
TABLE 6 MARKET SHARE BY LEADING CENTRAL NERVOUS SYSTEM PLAYERS, 2010 ($ MILLIONS/%) *23*
TABLE 7 LARGEST REVENUE GENERATING THERAPIES IN THE CENTRAL NERVOUS SYSTEM DISEASE ($ MILLIONS) *24*

CHAPTER FIVE: MARKETS BY DISEASE 25
SUMMARY OF MARKET DYNAMICS 25
TABLE 8 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS THROUGH 2015 ($ MILLIONS) *26*
PSYCHIATRY 26
MARKET DYNAMICS 26
TREATMENT AND MANAGEMENT 27
TABLE 9 CURRENT GLOBAL PSYCHIATRY MARKET, THROUGH 2010 ($ MILLIONS) *27*
TABLE 9 (CONTINUED) *28*
Seroquel 28
Zyprexa 29
Abilify 29
Geodon/Zeldox 30
Risperdal 31
TABLE 10 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 ($ MILLIONS) *32*
TABLE 11 FORECAST EPIDEMIOLOGY: PSYCHIATRY *32*
DEPRESSION 33
MARKET DYNAMICS 33

TREATMENT AND MANAGEMENT 33
TABLE 12 CURRENT GLOBAL DEPRESSION MARKET, THROUGH 2010 ($ MILLIONS) 33
Lexapro 34
Effexor 34
Cymbalta 35
GENERIC DRUG TRENDS: DEPRESSION 35
TABLE 13 GLOBAL DEPRESSION MARKET, THROUGH 2015 ($ MILLIONS) 36
TABLE 14 FORECAST EPIDEMIOLOGY: DEPRESSION 36
MULTIPLE SCLEROSIS AND PARKINSON'S 36
MARKET DYNAMICS 36
TABLE 15 CURRENT GLOBAL MS AND PARKINSON'S MARKET, THROUGH 2010 ($ MILLIONS) 37
TREATMENT AND MANAGEMENT 37
Requip 37
GENERIC DRUG TRENDS: PARKINSON'S 38
TABLE 16 GLOBAL MS AND PARKINSON'S MARKET, THROUGH 2015 ($ MILLIONS) 38
TABLE 17 FORECAST EPIDEMIOLOGY: MS/PARKINSONS, THROUGH 2015 39
EPILEPSY/CONVULSIONS 39
MARKET DYNAMICS 39
TABLE 18 CURRENT GLOBAL EPILEPSY MARKET, THROUGH 2010 ($ MILLIONS) 39
TABLE 18 (CONTINUED) 40
TREATMENT AND MANAGEMENT 40
Topamax 40
Lyrica 40
Lamictal 41
GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS 41
TABLE 19 GLOBAL EPILEPSY MARKET, THROUGH 2015 ($ MILLIONS) 42
ALZHEIMER'S 42
MARKET DYNAMICS 42
TABLE 20 CURRENT GLOBAL ALZHEIMER'S MARKET, THROUGH 2010 ($ MILLIONS) 43
TREATMENT AND MANAGEMENT 44
Aricept 44
Exelon 44
Namenda 45
TABLE 21 GLOBAL ALZHEIMER'S MARKET, THROUGH 2015 ($ MILLIONS) 45
TABLE 21 (CONTINUED) 46

GENERIC DRUG TRENDS: ALZHEIMER'S 46
ADHD AND NARCOLEPSY 46
MARKET DYNAMICS 46
TABLE 22 CURRENT GLOBAL ADHD / NARCOLEPSY MARKET, THROUGH 2010 ($ MILLIONS) *47*
TREATMENT AND MANAGEMENT 47
Concerta 47
Provigil 48
Vyvanse 48
Adderall 49
Strattera 49
TABLE 23 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015 ($ MILLIONS) *50*
GENERIC DRUG TRENDS: ADHD/NARCOLEPSY 50
MIGRAINE AND OTHER CNS DISEASE 50
MARKET DYNAMICS 50
TABLE 24 CURRENT GLOBAL MIGRAINE DISEASE MARKET, THROUGH 2010 ($ MILLIONS) *51*
TABLE 25 CURRENT GLOBAL OTHER CNS DISEASE MARKET, THROUGH 2010 ($ MILLIONS) *51*
TABLE 25 (CONTINUED) *52*
TREATMENT AND MANAGEMENT 52
Ambien 52
Lunesta 52
TABLE 26 GLOBAL MIGRAINE MARKET, THROUGH 2015 ($ MILLIONS) *53*
TABLE 27 GLOBAL OTHER CENTRAL NERVOUS SYSTEM MARKET THROUGH 2015 ($ MILLIONS) *54*

CHAPTER SIX: MARKETS BY GEOGRAPHY 55
SUMMARY 55
TABLE 28 CURRENT MARKET SIZE BY GEOGRAPHY, THROUGH 2010 ($ MILLIONS) *55*
METHODOLOGY 55
TABLE 29 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS) *56*
UNITED STATES 56
TABLE 30 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: PSYCHIATRY, THROUGH 2015 ..... *57*
TABLE 31 PEVALENCE OF EPIDEMIOLOGY IN THE U.S.: DEPRESSION, THROUGH 2015 ..... *57*
TABLE 32 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: STROKE, THROUGH 2015 ..... *57*
WESTERN EUROPE 57

TABLE 33 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: PSYCHIATRY, THROUGH 2015 ..... *58*
TABLE 34 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: DEPRESSION, THROUGH 2015 ..... *59*
TABLE 35 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: STROKE, THROUGH 2015 ..... *59*
JAPAN 59
TABLE 36 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: PSYCHIATRY, THROUGH 2015 ..... *60*
TABLE 37 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: DEPRESSION, THROUGH 2015 ..... *60*
EMERGING MARKETS 60
STRATEGIES TO ACCESS EMERGING MARKETS 60
EMERGING MARKETS FORECAST 61
BRAZIL 62
Market Overview 62
Regulatory Considerations 62
Patent Considerations 62
TABLE 38 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: PSYCHIATRY, THROUGH 2015 ..... *63*
TABLE 39 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: DEPRESSION, THROUGH 2015 ..... *63*
TABLE 40 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: STROKE, THROUGH 2015 ..... *64*
CHINA 64
Market Overview 64
Regulatory Considerations 64
Patent Considerations 65
TABLE 41 PREVALENCE OF EPIDEMIOLOGY IN CHINA: PSYCHIATRY, THROUGH 2015 ..... *66*
TABLE 42 PREVALENCE OF EPIDEMIOLOGY IN CHINA: DEPRESSION, THROUGH 2015 ..... *66*
TABLE 43 PREVALNCE OF EPIDEMIOLOGY IN CHINA: STROKE, THROUGH 2015 ..... *66*
INDIA 67
Market Overview 67
Regulatory Considerations 67
Patent Considerations 67
TABLE 44 PREVALENCE OF EPIDEMIOLOGY IN INDIA: PSYCHIATRY, THROUGH 2015 ..... *68*
TABLE 45 PREVALENCE OF EPIDEMIOLOGY IN INDIA: DEPRESSION, THROUGH 2015 ..... *68*
TABLE 46 PREVALENCE OF EPIDEMIOLOGY IN INDIA: STROKE, THROUGH 2015 ..... *68*

RUSSIA 69
Market Overview 69
Regulatory Considerations 69
Patent Considerations 69
TABLE 47 PEVALENCE OF EPIDEMIOLOGY IN RUSSIA: PSYCHIATRY, THROUGH 2015 70
TABLE 48 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: DEPRESSION, THROUGH 2015 70
TABLE 49 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: STROKE, THROUGH 2015 70
SOUTH AMERICA 70
TABLE 50 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: PSYCHIATRY, THROUGH 2015 71
TABLE 51 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: DEPRESSION, THROUGH 2015 71
TABLE 52 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA: STROKE, THROUGH 2015 71
CARIBBEAN 71
TABLE 53 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: PSYCHIATRY, THROUGH 2015 72
TABLE 54 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: DEPRESSION, THROUGH 2015 72
TABLE 55 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN: STROKE, THROUGH 2015 72
NORTHERN EUROPE 73
TABLE 56 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: PSYCHIATRY, THROUGH 2015 73
TABLE 57 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: DEPRESSION, THROUGH 2015 73
TABLE 58 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN EUROPE: STROKE, THROUGH 2015 73
CENTRAL AND EASTERN EUROPE 74
TABLE 59 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: PSYCHIATRY, THROUGH 2015 74
TABLE 60 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE: DEPRESSION, THROUGH 2015 74
TABLE 61 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND EASTERN EUROPE:STROKE, THROUGH 2015 74
AUSTRALIA 75
TABLE 62 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: PSYCHIATRY, THROUGH 2015 75
TABLE 63 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: DEPRESSION, THROUGH 2015 75

TABLE 64 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA: STROKE, THROUGH 2015 ..... *75*
ASIA–OTHER 76
TABLE 65 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: PSYCHIATRY, THROUGH 2015 ..... *76*
TABLE 66 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: DEPRESSION, THROUGH 2015 ..... *76*
TABLE 67 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER: STROKE, THROUGH 2015 ..... *76*
MIDDLE EAST 77
TABLE 68 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: PSYCHIATRY, THROUGH 2015 ..... *77*
TABLE 69 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: DEPRESSION, THROUGH 2015 ..... *77*
TABLE 70 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE EAST: STROKE, THROUGH 2015 ..... *77*
SOUTHERN AFRICA 78
TABLE 71 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: PSYCHIATRY, THROUGH 2015 ..... *78*
TABLE 72 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: DEPRESSION, THROUGH 2015 ..... *78*
TABLE 73 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA: STROKE, THROUGH 2015 ..... *78*
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST 79

CHAPTER SEVEN: PIPELINE ANALYSIS 80
TABLE 74 APPROVED PRODUCT FORECAST, 2009-2015 ($ MILLIONS) *80*
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 80
KEY TRENDS IN RESEARCH AND DEVELOPMENT 80
SNRIs Improve the Baseline Performance of Leading Depression Therapies 80
New Products Provide Larger Opportunities Compared to Product Extensions 81
Combination Products Yield Greater Therapeutic Response 81
Alzheimer's Therapy Continues to Receive Large and Important Investment 82
KEY PRODUCTS UNDER MAJOR CNS DISORDERS 82
Schizophrenia 82
Depression 83
Alzheimer's 83
Parkinson's Disease 84
Epilepsy 84

Insomnia 84
Attention Deficit Hyperactivity Disorder 85
Other Indications 85
2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY 85
PHASE III AND PENDING APPROVAL COMPOUNDS 85
Bapineuzumab (AAB–001)—Elan/Wyeth/Pfizer 85
TABLE 75 BAPINEUZUMAB (AAB–001)—ELAN/WYETH/PFIZER 85
Bapineuzumab (Continued) 86
Telcagepant (MK–0974)—Merck 87
TABLE 76 TELCAGEPANT (MK–0974)—MERCK 87
Telcagepant … (Continued) 88
Solanezumab (LY2062430)—Eli Lilly 89
TABLE 77 SOLANEZUMAB (LY2062430)—ELI LILLY 89
Semagacestat (LY450139)—Eli Lilly 90
TABLE 78 SEMAGACESTAT (LY450139)—ELI LILLY 90
Vilazodone—Clinical Data 91
TABLE 79 VILAZODONE—CLINICAL DATA 91
RECENTLY APPROVED/MARKETED DRUGS 92
Stedesa/Zebinix (eslicarbazepine acetate)—Dainippon Sumitomo (formerly Sepracor) 92
TABLE 80 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE)—DAINIPPON SUMITOMO (FORMERLY SEPRACOR) 92
Intuniv (guanfacine)—Shire 93
TABLE 81 INTUNIV (GUANFACINE)—SHIRE 93
Treximet (Sumatriptan and Naproxen)—GSK/Pozen 94
TABLE 82 TREXIMET (SUMATRIPTAN AND NAPROXEN)—GSK/POZEN 94
Treximet …(Continued) 95
Pristiq (desvenlafaxine)—Pfizer/Wyeth 96
TABLE 83 PRISTIQ (DESVENLAFAXINE)—PFIZER/WYETH 96
Vimpat (lacosamide)—UCB/Schwarz Pharma 97
TABLE 84 VIMPAT (LACOSAMIDE)—UCB/SCHWARZ PHARMA 97
TABLE 85 DEVELOPMENTAL PRODUCT FORECAST, 2009-2015 ($ MILLIONS) 98

CHAPTER EIGHT: COMPANY PROFILES 99
SUMMARY 99
TABLE 86 COMPANY REVENUE AND MARKET SHARE ANALYSIS, THROUGH 2010 ($ MILLIONS) 99
TABLE 86 (CONTINUED) 100
TABLE 87 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS) 100
TABLE 87 (CONTINUED) 101
COMPANIES 101
ABBOTT LABORATORIES 101

Business Overview 101
Therapeutic Areas..... 102
TABLE 88 ABBOTT LABORATORIES' LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 102
Corporate Strategy 102
ALLERGAN, INC. 102
Business Overview 102
Therapeutic Areas..... 103
TABLE 89 ALLERGAN'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 103
Corporate Strategy 103
Business Overview 103
Therapeutic Areas..... 104
TABLE 90 ASTELLAS' LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 104
Corporate Strategy 104
ASTRAZENECA 104
Business Overview 104
Therapeutic Areas..... 105
TABLE 91 ASTRAZENECA'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 105
Corporate Strategy 105
BAYER AG 106
Business Overview 106
Therapeutic Areas..... 106
TABLE 92 BAYER HEALTHCARE'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 107
Corporate Strategy 107
BIOGEN IDEC (FUMAPHARM AG) 107
Business Overview 107
Therapeutic Areas..... 107
TABLE 93 BIOGEN'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 107
Corporate Strategy 108
ELI LILLY & CO. 108
Business Overview 108
Therapeutic Areas..... 108
TABLE 94 ELI LILLY'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 108
Corporate Strategy 109
FOREST LABORATORIES, INC. 109
Business Overview 109
Therapeutic Areas..... 110

TABLE 95 FOREST LABORATORIES' LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *110*
Corporate Strategy 110
GLAXOSMITHKLINE (GSK) 110
Business Overview 110
Therapeutic Areas 111
TABLE 96 GLAXOSMITHKLINE'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *111*
Corporate Strategy 111
JOHNSON & JOHNSON 112
Business Overview 112
Therapeutic Areas 112
TABLE 97 JOHNSON & JOHNSON'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *112*
Corporate Strategy 112
MERCK & CO., INC. 113
Business Overview 113
Therapeutic Areas 113
TABLE 98 LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *114*
Corporate Strategy 114
Business Overview 114
Therapeutic Areas 114
TABLE 99 NOVARTIS' LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *115*
Corporate Strategy 115
PFIZER, INC. 115
Business Overview 115
Therapeutic Areas 116
TABLE 100 PFIZER'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *116*
Corporate Strategy 116
SANOFI–AVENTIS 117
Business Overview 117
Therapeutic Areas 117
TABLE 101 SANOFI–AVENTIS' LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *117*
Corporate Strategy 117
SHIRE PHARMACEUTICALS GROUP, PLC 118
Business Overview 118
Therapeutic Areas 118
TABLE 102 SHIRE'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) *118*
Corporate Strategy 118
Business Overview 119

Therapeutic Areas 119
TABLE 103 TAKEDA'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 119
Corporate Strategy 119
TEVA PHARMACEUTICAL INDUSTRIES LTD 120
Business Overview 120
Therapeutic Areas 120
TABLE 104 TEVA'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 120
Corporate Strategy 121
WATSON PHARMACEUTICALS, INC. 121
Business Overview 121
Therapeutic Areas 121
TABLE 105 WATSON'S LEADING PRODUCTS AND 2009 REVENUE ($ MILLIONS) 121
Corporate Strategy 121